These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26059208)

  • 1. No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression.
    Maquieira R; Haerle SK; Huber GF; Soltermann A; Haile SR; Stoeckli SJ; Broglie MA
    Eur Arch Otorhinolaryngol; 2016 Jul; 273(7):1841-8. PubMed ID: 26059208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p16 status and interval neck dissection findings after a 'clinically complete response' to chemoradiotherapy in oropharyngeal squamous cell carcinoma.
    Miah MS; Spielmann P; White SJ; Kennedy C; Kernohan N; Mountain RE; Cassasola R; Mahendran S
    J Laryngol Otol; 2015 Aug; 129(8):801-6. PubMed ID: 26087671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic outcomes of selective neck dissection in HPV-related oropharyngeal squamous cell carcinoma.
    Zenga J; Jackson RS; Graboyes EM; Sinha P; Lindberg M; Martin EJ; Ma D; Thorstad WL; Rich JT; Moore EJ; Haughey BH
    Laryngoscope; 2017 Mar; 127(3):623-630. PubMed ID: 27634021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing regional control in p16-negative oropharyngeal cancer: A propensity score-matched analysis of upfront neck dissection and definitive chemoradiotherapy.
    Lee TL; Fang WC; Lee IC; Lirng JF; Chang CF; Hsu YB; Chu PY; Wang YF; Yang MH; Chang PM; Wang LW; Tai SK
    J Chin Med Assoc; 2024 May; 87(5):516-524. PubMed ID: 38501795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Planned neck dissection after weekly docetaxel and concurrent radiotherapy for advanced oropharyngeal cancer].
    Tomita T; Ozawa H; Sakamoto K; Fujii R; Ogawa K; Fujii M; Yamashita T; Shinden S
    Nihon Jibiinkoka Gakkai Kaiho; 2007 Mar; 110(3):95-102. PubMed ID: 17419444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response evaluation of the neck in oropharyngeal cancer: Value of magnetic resonance imaging and influence of p16 in selecting patients for post-radiotherapy neck dissection.
    Lilja-Fischer JK; Jensen K; Eskildsen HW; Fink-Jensen V; Nielsen VE
    Acta Oncol; 2015; 54(9):1599-606. PubMed ID: 26198649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of p16 status on indication and outcome of salvage neck dissection in oropharyngeal cancer.
    Mueller SK; Mantsopoulos K; Semrau S; Agaimy A; Eckstein M; Traxdorf M; Gostian AO; Goncalves M; Sievert M; Haderlein M; Grundtner P; Hecht M; Koch M; Fietkau R; Iro H; Scherl C
    Acta Otolaryngol; 2021 Feb; 141(2):187-192. PubMed ID: 33108949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of transoral robotic surgery on the overall treatment of oropharyngeal cancer patients.
    Smith RV; Schiff BA; Garg M; Haigentz M
    Laryngoscope; 2015 Nov; 125 Suppl 10():S1-S15. PubMed ID: 26436491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
    Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
    Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodal response after 46 Gy of intensity-modulated radiotherapy is associated with human papillomavirus-related oropharyngeal carcinoma.
    Dronkers EAC; Koljenovic S; Verduijn GM; Baatenburg de Jong RJ; Hardillo JAU
    Laryngoscope; 2018 Oct; 128(10):2333-2340. PubMed ID: 29521420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of p16 and p53 expression in oropharyngeal squamous cell carcinomas.
    Shinohara S; Kikuchi M; Tona R; Kanazawa Y; Kishimoto I; Harada H; Imai Y; Usami Y
    Jpn J Clin Oncol; 2014 Mar; 44(3):232-40. PubMed ID: 24470584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma.
    Freitag J; Wald T; Kuhnt T; Gradistanac T; Kolb M; Dietz A; Wiegand S; Wichmann G
    Cancer; 2020 Jan; 126(9):1856-1872. PubMed ID: 32032442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy.
    Carpén T; Saarilahti K; Haglund C; Markkola A; Tarkkanen J; Hagström J; Mattila P; Mäkitie A
    Strahlenther Onkol; 2018 Aug; 194(8):759-770. PubMed ID: 29774396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction chemotherapy followed by concurrent chemoradiation versus concurrent chemoradiation alone in the definitive management of p16-positive oropharyngeal squamous cell carcinoma with low-neck or N3 disease.
    Bhattasali O; Han J; Thompson LDR; Buchschacher GL; Abdalla IA; Iganej S
    Oral Oncol; 2018 Mar; 78():151-155. PubMed ID: 29496043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p16 expression in carcinoma of unknown primary: diagnostic indicator and prognostic marker.
    Vent J; Haidle B; Wedemeyer I; Huebbers C; Siefer O; Semrau R; Preuss SF; Klussmann J
    Head Neck; 2013 Nov; 35(11):1521-6. PubMed ID: 23345170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated radiotherapy outcomes for oropharyngeal squamous cell carcinoma patients stratified by p16 status.
    Shoushtari A; Meeneghan M; Sheng K; Moskaluk CA; Thomas CY; Reibel JF; Levine PA; Jameson MJ; Keene K; Read PW
    Cancer; 2010 Jun; 116(11):2645-54. PubMed ID: 20225325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing trends in the management of the neck in oropharyngeal squamous cell carcinoma.
    Jouhi L; Atula T; Saarilahti K; Hagström J; Haglund C; Mohamed H; Mäkitie A; Keski-Säntti H
    Head Neck; 2017 Jul; 39(7):1412-1420. PubMed ID: 28464452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of the "violated neck" in the era of chemoradiation.
    Loyo M; Johnson JT; Westra WH; Chiosea SI; Gourin CG
    Laryngoscope; 2011 Nov; 121(11):2349-58. PubMed ID: 21993776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status.
    Shonka DC; Shoushtari AN; Thomas CY; Moskaluk C; Read PW; Reibel JF; Levine PA; Jameson MJ
    Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1126-32. PubMed ID: 19917926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.